Evofem Biosciences, Inc.
EVFM
$0.01
$0.0016.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.67% | -2.51% | 3.70% | 6.28% | 26.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.67% | -2.51% | 3.70% | 6.28% | 26.09% |
| Cost of Revenue | 7.97% | -18.51% | -39.60% | -41.12% | -44.87% |
| Gross Profit | 2.66% | 2.62% | 28.43% | 32.66% | 81.44% |
| SG&A Expenses | 19.87% | 20.24% | 7.36% | -1.39% | -32.31% |
| Depreciation & Amortization | 141.86% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.00% | -25.08% | -36.27% | -25.03% | -32.26% |
| Operating Income | 71.06% | 60.89% | 73.67% | 56.99% | 62.09% |
| Income Before Tax | 31.57% | -110.31% | -106.12% | -116.72% | -116.97% |
| Income Tax Expenses | -- | -105.26% | -100.00% | -100.00% | -100.00% |
| Earnings from Continuing Operations | 31.54% | -110.31% | -106.13% | -116.72% | -116.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.54% | -110.31% | -106.13% | -116.72% | -116.97% |
| EBIT | 71.06% | 60.89% | 73.67% | 56.99% | 62.09% |
| EBITDA | 77.72% | 69.36% | 78.43% | 59.55% | 62.40% |
| EPS Basic | 91.67% | -100.40% | -100.27% | -102.41% | 86.71% |
| Normalized Basic EPS | 82.68% | 97.70% | 99.71% | 97.71% | 98.01% |
| EPS Diluted | 92.99% | 90.56% | 99.14% | 97.30% | 95.44% |
| Normalized Diluted EPS | 81.42% | 82.55% | 99.13% | 96.77% | 97.63% |
| Average Basic Shares Outstanding | 120.49% | 278.78% | 685.71% | 1,501.71% | 2,482.24% |
| Average Diluted Shares Outstanding | 263.99% | 166.40% | 914.43% | 148.11% | 138.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |